Last reviewed · How we verify

Fenway Community Health — Portfolio Competitive Intelligence Brief

Fenway Community Health pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TRUVADA + Raltegravir TRUVADA + Raltegravir marketed Antiretroviral combination therapy (NRTI + INSTI) HIV reverse transcriptase and HIV integrase Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 shared drug class
  2. ViiV Healthcare · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fenway Community Health:

Cite this brief

Drug Landscape (2026). Fenway Community Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fenway-community-health. Accessed 2026-05-18.

Related